BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26967626)

  • 1. Truncation, modification, and optimization of MIG6(segment 2) peptide to target lung cancer-related EGFR.
    Yu XD; Yang R; Leng CJ
    Comput Biol Chem; 2016 Apr; 61():251-7. PubMed ID: 26967626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of MIG6 peptide from the nonbinder to binder of lung cancer-related EGFR by phosphorylation and cyclization.
    Li N; Wei M
    Artif Cells Nanomed Biotechnol; 2017 Aug; 45(5):1023-1028. PubMed ID: 27346601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coupled folding-upon-binding of human tumor suppressor MIG6 to lung cancer EGFR kinase domain and molecular trimming/stapling of MIG6-derived β-hairpins to target the coupling event.
    He Q; Xu S; Ma X; Ling T; Feng W; Lu X; Liu W; Chen Z
    Eur Biophys J; 2023 Feb; 52(1-2):17-25. PubMed ID: 36547692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.
    Maity TK; Venugopalan A; Linnoila I; Cultraro CM; Giannakou A; Nemati R; Zhang X; Webster JD; Ritt D; Ghosal S; Hoschuetzky H; Simpson RM; Biswas R; Politi K; Morrison DK; Varmus HE; Guha U
    Cancer Discov; 2015 May; 5(5):534-49. PubMed ID: 25735773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mig6 not only inhibits EGFR and HER2 but also targets HER3 and HER4 in a differential specificity: Implications for targeted esophageal cancer therapy.
    Zhong H; He J; Yu J; Li X; Mei Y; Hao L; Wu X
    Biochimie; 2021 Nov; 190():132-142. PubMed ID: 34293452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
    Zhang X; Pickin KA; Bose R; Jura N; Cole PA; Kuriyan J
    Nature; 2007 Nov; 450(7170):741-4. PubMed ID: 18046415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations.
    Endo H; Okami J; Okuyama H; Nishizawa Y; Imamura F; Inoue M
    Oncogene; 2017 May; 36(20):2824-2834. PubMed ID: 27893711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine phosphorylation of mig6 reduces its inhibition of the epidermal growth factor receptor.
    Wang Z; Raines LL; Hooy RM; Roberson H; Leahy DJ; Cole PA
    ACS Chem Biol; 2013 Nov; 8(11):2372-6. PubMed ID: 24004111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of Mig6 negatively regulates the ubiquitination and degradation of EGFR mutants in lung adenocarcinoma cell lines.
    Boopathy GTK; Lynn JLS; Wee S; Gunaratne J; Hong W
    Cell Signal; 2018 Mar; 43():21-31. PubMed ID: 29196224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.
    Park E; Kim N; Ficarro SB; Zhang Y; Lee BI; Cho A; Kim K; Park AKJ; Park WY; Murray B; Meyerson M; Beroukhim R; Marto JA; Cho J; Eck MJ
    Nat Struct Mol Biol; 2015 Sep; 22(9):703-711. PubMed ID: 26280531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the interactions of EGFR with phosphorylated Mig6 by molecular dynamics simulations and MM-PBSA calculations.
    Zhang Y; Zheng QC
    J Theor Biol; 2018 Jun; 447():118-125. PubMed ID: 29574142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of EGFR trafficking and cell signaling by Sprouty2 and MIG6 in lung cancer cells.
    Walsh AM; Lazzara MJ
    J Cell Sci; 2013 Oct; 126(Pt 19):4339-48. PubMed ID: 23868981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the molecular basis of EGFR kinase domain/MIG-6 peptide recognition complex using computational analyses.
    Moonrin N; Songtawee N; Rattanabunyong S; Chunsrivirot S; Mokmak W; Tongsima S; Choowongkomon K
    BMC Bioinformatics; 2015 Mar; 16():103. PubMed ID: 25885222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.
    Menezes SV; Kovacevic Z; Richardson DR
    J Biol Chem; 2019 Mar; 294(11):4045-4064. PubMed ID: 30679310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential parsing of EGFR endocytic flux among parallel internalization pathways in lung cancer cells with EGFR-activating mutations.
    Walsh AM; Lazzara MJ
    Integr Biol (Camb); 2014 Mar; 6(3):312-23. PubMed ID: 24445374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNAJB1 negatively regulates MIG6 to promote epidermal growth factor receptor signaling.
    Park SY; Choi HK; Seo JS; Yoo JY; Jeong JW; Choi Y; Choi KC; Yoon HG
    Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2722-30. PubMed ID: 26239118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tumor Suppressor MIG6 Controls Mitotic Progression and the G2/M DNA Damage Checkpoint by Stabilizing the WEE1 Kinase.
    Sasaki M; Terabayashi T; Weiss SM; Ferby I
    Cell Rep; 2018 Jul; 24(5):1278-1289. PubMed ID: 30067982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of epidermal growth factor receptor is associated with MIG6 expression.
    Nagashima T; Ushikoshi-Nakayama R; Suenaga A; Ide K; Yumoto N; Naruo Y; Takahashi K; Saeki Y; Taiji M; Tanaka H; Tsai SF; Hatakeyama M
    FEBS J; 2009 Sep; 276(18):5239-51. PubMed ID: 19674104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis.
    Izumchenko E; Sidransky D
    Cancer Discov; 2015 May; 5(5):472-4. PubMed ID: 25941338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational design of EGFR dimerization-disrupting peptides: A new strategy to combat drug resistance in targeted lung cancer therapy.
    Liu Q; Zhou J; Gao J; Ma W; Wang S; Xing L
    Biochimie; 2020 Sep; 176():128-137. PubMed ID: 32721503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.